The use of PS/PSN antiangiogenic drugs for the treatment of cancer has some advantages: AGFs such as FGFs and hepatocyte growth factor (HGF) act as pleiotropic cytokines that, in addition to neovascularization, induce proliferation of tumor cells. Here, HGF is linked to cancer.